PMID- 28277826
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20220316
IS  - 1744-8409 (Electronic)
IS  - 1744-666X (Linking)
VI  - 13
IP  - 5
DP  - 2017 May
TI  - Commonality of the IL-4/IL-13 pathway in atopic diseases.
PG  - 425-437
LID - 10.1080/1744666X.2017.1298443 [doi]
AB  - Allergy results from an aberrant Type 2 inflammatory response, triggered by a 
      wide range of environmental antigens (allergens) that lead to various immune 
      responses, culminating in the production of immunoglobulin E (IgE). Two key 
      cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and 
      perpetuation of the Type 2 response, and have been implicated in multiple atopic 
      diseases. Area covered: This review summarizes recent milestone developments that 
      have elucidated components of the pathogenesis of atopic diseases such as atopic 
      dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). 
      Expert commentary: Several therapeutic agents that selectively target 
      potentiators of the Type 2 pathway have shown efficacy in one or more of these 
      atopic diseases, but few agents have proven to be broadly applicable across all 
      three atopic diseases. Dupilumab, a human monoclonal antibody that simultaneously 
      inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical 
      efficacy in AD, asthma, and CSwNP. The fact that these diseases often occur as 
      comorbidities and respond to the same therapy suggests that there is a common 
      underlying pathogenic pathway, and that IL-4 and IL-13 cytokines are central to 
      regulating the pathogenesis of these atopic diseases.
FAU - Gandhi, Namita A
AU  - Gandhi NA
AD  - a Clinical Sciences , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , 
      USA.
FAU - Pirozzi, Gianluca
AU  - Pirozzi G
AD  - b Research and Development , Sanofi, Bridgewater , New Jersey , USA.
FAU - Graham, Neil M H
AU  - Graham NMH
AD  - c Project Direction , Regeneron Pharmaceuticals, Inc. , Tarrytown , New York , 
      USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20170315
PL  - England
TA  - Expert Rev Clin Immunol
JT  - Expert review of clinical immunology
JID - 101271248
RN  - 0 (Allergens)
RN  - 0 (Interleukin-13)
RN  - 207137-56-2 (Interleukin-4)
SB  - IM
MH  - Allergens/immunology
MH  - Asthma/*immunology
MH  - Chronic Disease
MH  - Dermatitis, Atopic/*immunology
MH  - Humans
MH  - Interleukin-13/*metabolism
MH  - Interleukin-4/*metabolism
MH  - Molecular Targeted Therapy
MH  - Nasal Polyps/*immunology
MH  - Signal Transduction
MH  - Sinusitis/*immunology
MH  - Th2 Cells/*immunology
OTO - NOTNLM
OT  - Type 2 pathway
OT  - asthma
OT  - atopic dermatitis
OT  - dupilumab
OT  - interleukin-13
OT  - interleukin-4
OT  - lebrikizumab
OT  - nasal polyposis
OT  - tralokinumab
EDAT- 2017/03/10 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - 10.1080/1744666X.2017.1298443 [doi]
PST - ppublish
SO  - Expert Rev Clin Immunol. 2017 May;13(5):425-437. doi: 
      10.1080/1744666X.2017.1298443. Epub 2017 Mar 15.